Add Yahoo as a preferred source to see more of our stories on Google. Originally appeared on E! Online Matthew Fox doesn’t plan on getting lost in these lush woods. Indeed, The Madison actor shared ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

This is read by an automated voice. Please report any issues or inconsistencies here. One widely held view of Harry Styles is that he’s a cool guy who makes boring music. What if he’s actually a ...

A royal reporter shared some insight into why they switched up their hello Aaron Chown / POOL / AFP via Getty Kate Middleton and Princess Anne were among the British royals to attend the Commonwealth ...

A new Harry Styles era is upon us, as he just dropped his fourth studio album, Kiss All The Time. Disco, Occasionally. To celebrate, the Grammy winner is hosting more than a dozen pop-up shops around ...

Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk. The Danish company is less diversified than current and future competitors, and increasingly exposed to ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of 2024. Now, the momentum has dissipated, and most companies are bracing for ...

Every time Hilary publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. 10 stocks we like better than Eli Lilly ...

In the latest clinical trial, Eli Lilly's retatrutide helped participants lose up to 28.7% of their body weight. Some participants dropped out of the trial because they lost too much weight. The drug ...